← All trials
NCT05542862
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 7, 2022
- Primary completion
- Apr 16, 2023
- Completion date
- Jun 30, 2023
- First posted
- Sep 16, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 150
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vaxine Pty LtdLead sponsor
- CinnagenCollaborator
- Vaxine Pty LtdStudy director
- Australian Respiratory and Sleep Medicine InstituteCollaborator
- Australian Respiratory and Sleep Medicine InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.